Mike Vincent, MD, PhD, is Senior Vice President and Chief Scientific Officer of the Inflammation and Immunology Research Unit, leading the scientific pipeline for Rheumatology, Gastroenterology and Dermatology specialties through the end of phase 2. Dr. Vincent earned his BA, PhD, and MD degrees from Indiana University. He completed his residency and began his post-doctoral and rheumatology training at the University of Vermont, completing his fellowship at Brigham and Women’s Hospital. His research while on faculty at Harvard centered on human T cell-dendritic cell interactions, and basic mechanisms of autoimmunity. Since joining Pfizer in 2011, he has held several scientific leadership roles, most recently as Clinical Head for Pharmatherapeutics in Cambridge, MA. Over this period, he has had responsibility for clinical and translational science in the Inflammation and Immunology, Rare Disease and the Cardiovascular and Metabolic Disease Research Units, and the Centers for Therapeutic Innovation. Before joining Pfizer, Dr. Vincent held positions of increasing responsibility within Medical Sciences at Amgen, ultimately leading early clinical development for the Immunology and Neuroscience therapeutic areas.

Michael S. Vincent has broad interests in the Infectious Diseases and Computational Precision Medicine. His research thus far has focused on She is specialized in mucosal immunology, autoimmunity, and gut microbiome, with advanced technical skills in the animal models of inflammation, multicolor fluorescence-activated cell sorting, cell-based assays, and molecular biology techniques.